Abstract
To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
| Original language | English |
|---|---|
| Pages (from-to) | 63-68 |
| Number of pages | 6 |
| Journal | Japanese Journal of Antibiotics |
| Volume | 49 |
| Issue number | 2 |
| Publication status | Published - 02-1996 |
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases
Other files and links
Fingerprint Dive into the research topics of 'A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method'. Together they form a unique fingerprint.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method. / Saito, Atsushi; Sakamoto, Mitsuo; Saito, Akira; Ohmichi, Mitsuhide; Hiraga, Yohmei; Kikuchi, Kenjiro; Ohsaki, Yoshinobu; Sasaki, Nobuhiro; Matsumoto, Hiroyuki; Suda, Toshihiro; Tsuzino, Moriyasu; Hirai, Yuichi; Inoue, Hiroshi; Yoshida, Masami; Mouri, Takashi; Kobayashi, Hitoshi; Chiba, Shinichi; Ito, Takashi; Moriya, Katsuyoshi; Bando, Takeshi; Takeuchi, Kenichi; Tanifuji, Yukio; Shirato, Kunio; Tanno, Yasuo; Takahashi, Makoto; Sakamoto, Masahiro; Nukiwa, Toshihiro; Watanabe, Akira; Sato, Kazuo; Homma, Mitsunobu; Ito, Nobuo; Yanase, Kenji; Dote, Kunio; Ohishi, Akira; Fukuda, Kiyoshi; Katsu, Masataka; Sakai, Osamu; Shiba, Kohya; Kobayashi, Hiroyuki; Sakayori, Susumu; Miura, Hiroshi; Watanabe, Hidehiro; Shimada, Kaoru; Oka, Shinichi; Sugiyama, Hirotaka; Inamatsu, Takashi; Sano, Yasuyuki; Arai, Yasuo; Otomo, Mamoru; Sukou, Matsunobu; Kobayashi, Hideo; Sikata, Susumu; Shishido, Harumi; Tsuchihashi, Keiko; Nakata, Koichiro; Tsuboi, Eiyasu; Nakatani, Tatsuo; Nakamori, Yoshitaka; Hayashi, Izumi; Koyama, Masaru; Okubo, Takao; Tani, Kenji; Kaneko, Tamotsu; Matsumura, Masanori; Takagi, Shigeto; Hasegawa, Hideyuki; Numata, Hiroyuki; Fukuda, Tsutomu; Irimajiri, Shoichiro; Matsuoka, Yasuo; Obana, Mitsuo; Matsumoto, Fumio; Sakurai, Iwao; Odagiri, Shigeki; Takahashi, Kenichi; Suzuki, Kaneo; Arakawa, Masaaki; Wada, Koichi; Iwata, Fumihide; Shimazu, Yoshinori; Sega, Hiroyuki; Tsukada, Hiroki; Kawashima, Takashi; Aoki, Nobuki; Suzuki, Yasutoshi; Sekine, Osamu; Sato, Atsuhiko; Nakano, Yutaka; Tamura, Ryoji; Suganuma, Hideki; Shirai, Masahiro; Kawakatsu, Sumio; Watanabe, Takayoshi; Akiyama, Jinichiro; Yagi, Takeshi; Torikai, Katsutaka; Fukaya, Syusaku; Mizutani, Akiei; Takeuchi, Toshihiko; Yamada, Yasuo; Hanaki, Hidekazu; Kawakami, Makoto; Hayashi, Yoshimitsu; Tashiro, Tomoyuki; Nomura, Ryuji; Takagi, Kenzo; Noda, Yasunobu; Gonda, Hideo; Taniguchi, Hiroyuki; Izumi, Saburo; Kuze, Fumiyuki; Niimi, Akio; Mochizuki, Yosiro; Nakahara, Yasuji; Kawamura, Tetsuji; Kishimoto, Tadamitsu; Tanio, Yoshiro; Igarashi, Tsuyoshi; Komuta, Kiyoshi; Ito, Masami; Okumoto, Takeshi; Mori, Masahide; Jozaki, Kiyoshi; Yonezu, Seibun; Miki, Fumio; Higashino, Kazuya; Nakano, Takashi; Miyake, Mitsutomi; Nishian, Toshihiko; Iida, Shinichiro; Yamamoto, Sayaka; Maebo, Akio; Yoshimoto, Takahiko; Sonoda, Takashi; Nakagawa, Masakiyo; Hirabayashi, Masataka; Togawa, Naoki; Yoshida, Masao; Kawai, Yoshitaka; Soejima, Rinzo; Okimoto, Niro; Matsushima, Toshiharu; Kimura, Makoto; Yamakido, Michio; Ishioka, Shinichi; Kuwahara, Masao; Mochizuki, Nobuhiro; Miyazawa, Teruomi; Doi, Masao; Arita, Kenichi; Daido, Kazuhiro; Ejima, Tsuyoshi; Sawae, Yoshiro; Takaki, Koji; Yoshida, Minoru; Aritomi, Takamichi; Oizumi, Kotaro; Ichikawa, Yoichiro; Shiraishi, Tsuneaki; Mitsutake, Yoshiyuki; Tanaka, Fumio; Ohtsuka, Takaoki; Kawahara, Masashi; Kawaguchi, Shinzo; Kawayama, Tomotaka; Sato, Yoshihiro; Honda, Yoshiaki; Ishibashi, Tsuneo; Takamoto, Masahiro; Kajiki, Akira; Harada, Yasuko; Ando, Masayuki; Suga, Moritaka; Tokunaga, Katsumasa; Shima, Kiyoshi; Takenaka, Shinobu; Hara, Kohei; Kohno, Shigeru; Kaku, Mitsuo; Koga, Nobuhiro; Inoue, Yuichi; Yamasita, Yuko; Sakata, Shingo; Fujii, Takeshi; Irifune, Kenji; Shimoguchi, Kazunori; Miyazaki, Yoshitsugu; Matsumoto, Keizo; Nagatake, Tsuyoshi; Takasugi, Masakazu; Fujishita, Mikio; Nasu, Masaru; Yamasaki, Tohru; Goto, Yoichiro; Nakama, Kaoru; Inoue, Soichi; Matsukura, Shigeru; Mashimoto, Hideo; Mukae, Hiroshi; Saito, Atsushi; Fukuhara, Hiroshi; Oyakawa, Tominori; Deguchi, Koichi; Nakashima, Mitsuyoshi.
In: Japanese Journal of Antibiotics, Vol. 49, No. 2, 02.1996, p. 63-68.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method
AU - Saito, Atsushi
AU - Sakamoto, Mitsuo
AU - Saito, Akira
AU - Ohmichi, Mitsuhide
AU - Hiraga, Yohmei
AU - Kikuchi, Kenjiro
AU - Ohsaki, Yoshinobu
AU - Sasaki, Nobuhiro
AU - Matsumoto, Hiroyuki
AU - Suda, Toshihiro
AU - Tsuzino, Moriyasu
AU - Hirai, Yuichi
AU - Inoue, Hiroshi
AU - Yoshida, Masami
AU - Mouri, Takashi
AU - Kobayashi, Hitoshi
AU - Chiba, Shinichi
AU - Ito, Takashi
AU - Moriya, Katsuyoshi
AU - Bando, Takeshi
AU - Takeuchi, Kenichi
AU - Tanifuji, Yukio
AU - Shirato, Kunio
AU - Tanno, Yasuo
AU - Takahashi, Makoto
AU - Sakamoto, Masahiro
AU - Nukiwa, Toshihiro
AU - Watanabe, Akira
AU - Sato, Kazuo
AU - Homma, Mitsunobu
AU - Ito, Nobuo
AU - Yanase, Kenji
AU - Dote, Kunio
AU - Ohishi, Akira
AU - Fukuda, Kiyoshi
AU - Katsu, Masataka
AU - Sakai, Osamu
AU - Shiba, Kohya
AU - Kobayashi, Hiroyuki
AU - Sakayori, Susumu
AU - Miura, Hiroshi
AU - Watanabe, Hidehiro
AU - Shimada, Kaoru
AU - Oka, Shinichi
AU - Sugiyama, Hirotaka
AU - Inamatsu, Takashi
AU - Sano, Yasuyuki
AU - Arai, Yasuo
AU - Otomo, Mamoru
AU - Sukou, Matsunobu
AU - Kobayashi, Hideo
AU - Sikata, Susumu
AU - Shishido, Harumi
AU - Tsuchihashi, Keiko
AU - Nakata, Koichiro
AU - Tsuboi, Eiyasu
AU - Nakatani, Tatsuo
AU - Nakamori, Yoshitaka
AU - Hayashi, Izumi
AU - Koyama, Masaru
AU - Okubo, Takao
AU - Tani, Kenji
AU - Kaneko, Tamotsu
AU - Matsumura, Masanori
AU - Takagi, Shigeto
AU - Hasegawa, Hideyuki
AU - Numata, Hiroyuki
AU - Fukuda, Tsutomu
AU - Irimajiri, Shoichiro
AU - Matsuoka, Yasuo
AU - Obana, Mitsuo
AU - Matsumoto, Fumio
AU - Sakurai, Iwao
AU - Odagiri, Shigeki
AU - Takahashi, Kenichi
AU - Suzuki, Kaneo
AU - Arakawa, Masaaki
AU - Wada, Koichi
AU - Iwata, Fumihide
AU - Shimazu, Yoshinori
AU - Sega, Hiroyuki
AU - Tsukada, Hiroki
AU - Kawashima, Takashi
AU - Aoki, Nobuki
AU - Suzuki, Yasutoshi
AU - Sekine, Osamu
AU - Sato, Atsuhiko
AU - Nakano, Yutaka
AU - Tamura, Ryoji
AU - Suganuma, Hideki
AU - Shirai, Masahiro
AU - Kawakatsu, Sumio
AU - Watanabe, Takayoshi
AU - Akiyama, Jinichiro
AU - Yagi, Takeshi
AU - Torikai, Katsutaka
AU - Fukaya, Syusaku
AU - Mizutani, Akiei
AU - Takeuchi, Toshihiko
AU - Yamada, Yasuo
AU - Hanaki, Hidekazu
AU - Kawakami, Makoto
AU - Hayashi, Yoshimitsu
AU - Tashiro, Tomoyuki
AU - Nomura, Ryuji
AU - Takagi, Kenzo
AU - Noda, Yasunobu
AU - Gonda, Hideo
AU - Taniguchi, Hiroyuki
AU - Izumi, Saburo
AU - Kuze, Fumiyuki
AU - Niimi, Akio
AU - Mochizuki, Yosiro
AU - Nakahara, Yasuji
AU - Kawamura, Tetsuji
AU - Kishimoto, Tadamitsu
AU - Tanio, Yoshiro
AU - Igarashi, Tsuyoshi
AU - Komuta, Kiyoshi
AU - Ito, Masami
AU - Okumoto, Takeshi
AU - Mori, Masahide
AU - Jozaki, Kiyoshi
AU - Yonezu, Seibun
AU - Miki, Fumio
AU - Higashino, Kazuya
AU - Nakano, Takashi
AU - Miyake, Mitsutomi
AU - Nishian, Toshihiko
AU - Iida, Shinichiro
AU - Yamamoto, Sayaka
AU - Maebo, Akio
AU - Yoshimoto, Takahiko
AU - Sonoda, Takashi
AU - Nakagawa, Masakiyo
AU - Hirabayashi, Masataka
AU - Togawa, Naoki
AU - Yoshida, Masao
AU - Kawai, Yoshitaka
AU - Soejima, Rinzo
AU - Okimoto, Niro
AU - Matsushima, Toshiharu
AU - Kimura, Makoto
AU - Yamakido, Michio
AU - Ishioka, Shinichi
AU - Kuwahara, Masao
AU - Mochizuki, Nobuhiro
AU - Miyazawa, Teruomi
AU - Doi, Masao
AU - Arita, Kenichi
AU - Daido, Kazuhiro
AU - Ejima, Tsuyoshi
AU - Sawae, Yoshiro
AU - Takaki, Koji
AU - Yoshida, Minoru
AU - Aritomi, Takamichi
AU - Oizumi, Kotaro
AU - Ichikawa, Yoichiro
AU - Shiraishi, Tsuneaki
AU - Mitsutake, Yoshiyuki
AU - Tanaka, Fumio
AU - Ohtsuka, Takaoki
AU - Kawahara, Masashi
AU - Kawaguchi, Shinzo
AU - Kawayama, Tomotaka
AU - Sato, Yoshihiro
AU - Honda, Yoshiaki
AU - Ishibashi, Tsuneo
AU - Takamoto, Masahiro
AU - Kajiki, Akira
AU - Harada, Yasuko
AU - Ando, Masayuki
AU - Suga, Moritaka
AU - Tokunaga, Katsumasa
AU - Shima, Kiyoshi
AU - Takenaka, Shinobu
AU - Hara, Kohei
AU - Kohno, Shigeru
AU - Kaku, Mitsuo
AU - Koga, Nobuhiro
AU - Inoue, Yuichi
AU - Yamasita, Yuko
AU - Sakata, Shingo
AU - Fujii, Takeshi
AU - Irifune, Kenji
AU - Shimoguchi, Kazunori
AU - Miyazaki, Yoshitsugu
AU - Matsumoto, Keizo
AU - Nagatake, Tsuyoshi
AU - Takasugi, Masakazu
AU - Fujishita, Mikio
AU - Nasu, Masaru
AU - Yamasaki, Tohru
AU - Goto, Yoichiro
AU - Nakama, Kaoru
AU - Inoue, Soichi
AU - Matsukura, Shigeru
AU - Mashimoto, Hideo
AU - Mukae, Hiroshi
AU - Saito, Atsushi
AU - Fukuhara, Hiroshi
AU - Oyakawa, Tominori
AU - Deguchi, Koichi
AU - Nakashima, Mitsuyoshi
PY - 1996/2
Y1 - 1996/2
N2 - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
AB - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=29344459609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29344459609&partnerID=8YFLogxK
M3 - Review article
C2 - 8721077
AN - SCOPUS:29344459609
VL - 49
SP - 63
EP - 68
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
SN - 0368-2781
IS - 2
ER -